157 related articles for article (PubMed ID: 33619912)
1. High rates of long-term progression in HIV-1-positive elite controllers.
Borrell M; Fernández I; Etcheverrry F; Ugarte A; Plana M; Leal L; García F
J Int AIDS Soc; 2021 Feb; 24(2):e25675. PubMed ID: 33619912
[TBL] [Abstract][Full Text] [Related]
2. Rate and predictors of progression in elite and viremic HIV-1 controllers.
Leon A; Perez I; Ruiz-Mateos E; Benito JM; Leal M; Lopez-Galindez C; Rallon N; Alcami J; Lopez-Aldeguer J; Viciana P; Rodriguez C; Grau E; Iribarren J; Gatell JM; Garcia F;
AIDS; 2016 May; 30(8):1209-20. PubMed ID: 26854807
[TBL] [Abstract][Full Text] [Related]
3. Elite controllers long-term non progressors present improved survival and slower disease progression.
Capa L; Ayala-Suárez R; De La Torre Tarazona HE; González-García J; Del Romero J; Alcamí J; Díez-Fuertes F
Sci Rep; 2022 Sep; 12(1):16356. PubMed ID: 36175445
[TBL] [Abstract][Full Text] [Related]
4. Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection.
Pernas M; Tarancón-Diez L; Rodríguez-Gallego E; Gómez J; Prado JG; Casado C; Dominguez-Molina B; Olivares I; Coiras M; León A; Rodriguez C; Benito JM; Rallón N; Plana M; Martinez-Madrid O; Dapena M; Iribarren JA; Del Romero J; García F; Alcamí J; Muñoz-Fernández M; Vidal F; Leal M; Lopez-Galindez C; Ruiz-Mateos E
J Virol; 2018 Mar; 92(5):. PubMed ID: 29212942
[TBL] [Abstract][Full Text] [Related]
5. Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers.
Chereau F; Madec Y; Sabin C; Obel N; Ruiz-Mateos E; Chrysos G; Fidler S; Lehmann C; Zangerle R; Wittkop L; Reiss P; Hamouda O; Estrada Perez V; Leal M; Mocroft A; Garcia De Olalla P; Ammassari A; D'Arminio Monforte A; Mussini C; Segura F; Castagna A; Cavassini M; Grabar S; Morlat P; De Wit S; Lambotte O; Meyer L;
PLoS One; 2017; 12(4):e0173893. PubMed ID: 28380038
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers.
Vigneault F; Woods M; Buzon MJ; Li C; Pereyra F; Crosby SD; Rychert J; Church G; Martinez-Picado J; Rosenberg ES; Telenti A; Yu XG; Lichterfeld M
J Virol; 2011 Mar; 85(6):3015-9. PubMed ID: 21177805
[TBL] [Abstract][Full Text] [Related]
7. Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers.
Ganesh A; Lemongello D; Lee E; Peterson J; McLaughlin BE; Ferre AL; Gillespie GM; Fuchs D; Deeks SG; Hunt PW; Price RW; Spudich SS; Shacklett BL
AIDS Res Hum Retroviruses; 2016 Aug; 32(8):791-800. PubMed ID: 27019338
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
[TBL] [Abstract][Full Text] [Related]
9. CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory.
Boufassa F; Saez-Cirion A; Lechenadec J; Zucman D; Avettand-Fenoel V; Venet A; Rouzioux C; Delfraissy JF; Lambotte O; Meyer L;
PLoS One; 2011 Apr; 6(4):e18726. PubMed ID: 21533035
[TBL] [Abstract][Full Text] [Related]
10. Brief Report: Identification of Elite and Viremic Controllers From a Large Urban HIV Ambulatory Center in Kampala, Uganda.
Kayongo A; Gonzalo-Gil E; Gümüşgöz E; Niwaha AJ; Semitala F; Kalyesubula R; Bagaya BS; Joloba ML; Sutton RE
J Acquir Immune Defic Syndr; 2018 Nov; 79(3):394-398. PubMed ID: 30063647
[TBL] [Abstract][Full Text] [Related]
11. Two Distinct Mechanisms Leading to Loss of Virological Control in the Rare Group of Antiretroviral Therapy-Naive, Transiently Aviremic Children Living with HIV.
Vieira VA; Adland E; Grayson NE; Csala A; Richards F; Dacon C; Athavale R; Tsai MH; D'Souza R; Muenchhoff M; Bonsall D; Jooste P; Goulder PJR
J Virol; 2022 Jan; 96(2):e0153521. PubMed ID: 34757843
[TBL] [Abstract][Full Text] [Related]
12. Normal T-cell activation in elite controllers with preserved CD4+ T-cell counts.
Bansal A; Sterrett S; Erdmann N; Westfall AO; Dionne-Odom J; Overton ET; Goepfert PA
AIDS; 2015 Nov; 29(17):2245-54. PubMed ID: 26544698
[TBL] [Abstract][Full Text] [Related]
13. Case report: mechanisms of HIV elite control in two African women.
Moosa Y; Tanko RF; Ramsuran V; Singh R; Madzivhandila M; Yende-Zuma N; Abrahams MR; Selhorst P; Gounder K; Moore PL; Williamson C; Abdool Karim SS; Garrett NJ; Burgers WA
BMC Infect Dis; 2018 Jan; 18(1):54. PubMed ID: 29370775
[TBL] [Abstract][Full Text] [Related]
14. Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips" and Immune Activation in the ANRS CO21 CODEX Study.
Noel N; Lerolle N; Lécuroux C; Goujard C; Venet A; Saez-Cirion A; Avettand-Fenoël V; Meyer L; Boufassa F; Lambotte O;
PLoS One; 2015; 10(7):e0131922. PubMed ID: 26146823
[TBL] [Abstract][Full Text] [Related]
15. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
16. Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers.
Walker WE; Kurscheid S; Joshi S; Lopez CA; Goh G; Choi M; Barakat L; Francis J; Fisher A; Kozal M; Zapata H; Shaw A; Lifton R; Sutton RE; Fikrig E
J Virol; 2015 May; 89(10):5502-14. PubMed ID: 25740989
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers.
Rosás-Umbert M; Llano A; Bellido R; Olvera A; Ruiz-Riol M; Rocafort M; Fernández MA; Cobarsi P; Crespo M; Dorrell L; Del Romero J; Alcami J; Paredes R; Brander C; Mothe B
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487276
[TBL] [Abstract][Full Text] [Related]
18. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital.
Todd S; Rafferty P; Walker E; Hunter M; Dinsmore WW; Donnelly CM; McCarty EJ; Quah SP; Emerson CR
Int J STD AIDS; 2017 Oct; 28(11):1074-1081. PubMed ID: 28118801
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV.
Grabar S; Selinger-Leneman H; Abgrall S; Pialoux G; Weiss L; Costagliola D
AIDS; 2009 Jun; 23(9):1163-9. PubMed ID: 19444075
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with immunological and virological discordant responses to highly active antiretroviral therapy among adult HIV positive individuals in Ethiopia: A cross-sectional study.
Manaye GA; Abateneh DD; Asmare WN; Abebe M
Medicine (Baltimore); 2021 Nov; 100(47):e27624. PubMed ID: 34964727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
